[ALKS] Alkermes plc


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 57.99 Change: 1.68 (2.98%)
Ext. hours: Change: 0 (0%)

chart ALKS

Refresh chart

Strongest Trends Summary For ALKS

ALKS is in the long-term down -58% in 3 years and down -76% below S&P in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA to treat schizophrenia; AMPYRA/FAMPYRA to treat multiple sclerosis; BYDUREON to treat type II diabetes; VIVITROL for alcohol and opioid dependence; TRICOR, LIPANTHYL, LIPIDIL, and SUPRALIP to lower cholesterol; ZANAFLEX for muscle spasticity; AVINZA for moderate to severe pain; EMEND to treat nausea associated with chemotherapy and surgery; and FOCALIN XR and RITALIN LA for attention deficit and hyperactivity disorder. Its products also include MEGACE ES to treat cachexia associated with AIDS; LUVOX CR for obsessive-compulsive disorder; RAPAMUNE to prevent renal transplant rejection; NAPRELAN for mild to moderate pain indications; VERAPAMIL SR, VERELAN, VERELAN PM, VERAPAMIL PM, VERECAPS, UNIVER, and AFEDlTAB CR for hypertension; DILZEM SR, DILZEM XL, DILTELAN, and CARDIZEM CD for hypertension a

Fundamental Ratios
Shares Outstanding EPS-1.31 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 5.08% Sales Growth - Q/Q-7.96% P/E-43.63
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-1.89% ROE-2.56% ROI-2.04%
Current Ratio8.79 Quick Ratio8.36 Long Term Debt/Equity0.39 Debt Ratio0.08
Gross Margin72.77% Operating Margin-15.17% Net Profit Margin-5.6% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities17.94 M Cash From Investing Activities-31.78 M Cash From Operating Activities-13.33 M Gross Profit120.95 M
Net Profit-46.11 M Operating Profit-52.52 M Total Assets1.91 B Total Current Assets1.02 B
Total Current Liabilities134.22 M Total Debt354.81 M Total Liabilities515.68 M Total Revenue151.37 M
Technical Data
High 52 week61.63 Low 52 week24.85 Last close24.85 Last change-1.78%
RSI9.78 Average true range1.04 Beta1.3 Volume502.8 K
Simple moving average 20 days-13.22% Simple moving average 50 days-22.94% Simple moving average 200 days-36.99%
Performance Data
Performance Week-5.51% Performance Month-25.06% Performance Quart-31.73% Performance Half-44.17%
Performance Year-57.8% Performance Year-to-date-29.22% Volatility daily3.38% Volatility weekly7.57%
Volatility monthly15.51% Volatility yearly53.73% Relative Volume195.73% Average Volume1.08 M
New High New Low


2020-05-29 11:31:03 | Alkermes ALKS Up 21.6% Since Last Earnings Report: Can It Continue?

2020-05-27 07:00:00 | Alkermes Highlights New Data From Schizophrenia Portfolio at the American Society of Clinical Psychopharmacology 2020 Annual Meeting

2020-05-20 07:00:00 | Journal of Clinical Psychiatry Publishes Data from Alkermes' ALPINE Study in Patients With Schizophrenia

2020-05-14 07:00:00 | Alkermes Presents New Data From Schizophrenia Portfolio at Virtual 2020 Congress of the Schizophrenia International Research Society

2020-05-11 07:00:00 | Alkermes Announces Expansion of Patient Services and Provider Network to Support Uninterrupted Access to ARISTADA® and VIVITROL® During COVID-19 Crisis

2020-05-06 16:00:00 | Alkermes Announces Upcoming Presentation at the Bank of America Securities Virtual Health Care Conference

2020-05-01 09:45:39 | Analysts Have Lowered Expectations For Alkermes plc NASDAQ:ALKS After Its Latest Results

2020-04-30 11:12:03 | Alkermes' ALKS Q1 Earnings Increase Y/Y, Revenues Beat

2020-04-29 17:56:11 | Edited Transcript of ALKS earnings conference call or presentation 29-Apr-20 12:00pm GMT

2020-04-29 15:00:47 | Alkermes PLC ALKS Q1 2020 Earnings Call Transcript

2020-04-29 07:47:45 | Alkermes: Q1 Earnings Insights

2020-04-29 07:00:00 | Alkermes Plc Reports First Quarter 2020 Financial Results and Provides COVID-19 Related Business Update

2020-04-28 11:58:03 | What's in Store for Innoviva INVA This Earnings Season?

2020-04-28 11:40:03 | ANIK vs. ALKS: Which Stock Should Value Investors Buy Now?

2020-04-22 16:00:00 | Alkermes to Host Conference Call to Discuss First Quarter 2020 Financial Results

2020-04-22 08:49:12 | Why Alkermes ALKS Might Surprise This Earnings Season

2020-04-22 07:00:00 | Alkermes Announces Publication of Preclinical Data for ALKS 4230 in the Journal for ImmunoTherapy of Cancer

2020-04-16 12:31:04 | Alkermes ALKS Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

2020-04-04 10:02:00 | Is Alkermes NASDAQ:ALKS Using Debt Sensibly?

2020-03-29 22:25:01 | Here is What Hedge Funds Think About Alkermes Plc ALKS

2020-03-14 11:30:03 | Alkermes ALKS Down 8.6% Since Last Earnings Report: Can It Rebound?

2020-03-04 07:00:00 | Journal of Clinical Psychiatry Publishes Data from Alkermes' Phase 3 ENLIGHTEN-1 Efficacy Study of ALKS 3831 in Patients With Schizophrenia

2020-02-28 05:32:14 | The Independent Director of Alkermes plc NASDAQ:ALKS, Nancy Wysenski, Just Bought 161% More Shares

2020-02-24 16:00:00 | Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 40th Annual Health Care Conference

2020-02-24 14:08:10 | Alkermes, Inc. -- Moody's assigns Ba3 to Alkermes' sr. secured term loan; stable outlook

2020-02-19 16:01:00 | Alkermes to Present at the 9th Annual SVB Leerink Global Healthcare Conference

2020-02-17 17:49:25 | Edited Transcript of ALKS earnings conference call or presentation 13-Feb-20 1:00pm GMT

2020-02-14 10:49:03 | Alkermes' ALKS Earnings and Revenues Beat Estimates in Q4

2020-02-14 10:46:00 | Alkermes Reported More Revenue Than Expected. Here’s Why the Stock Is Falling.

2020-02-13 09:32:02 | Alkermes ALKS Tops Q4 Earnings and Revenues Beat Estimates

2020-02-13 09:05:02 | Alkermes ALKS Q4 Earnings and Revenues Top Estimates

2020-02-13 08:05:12 | The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO

2020-02-13 07:00:00 | Alkermes Plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2019 and Provides Financial Expectations for 2020

2020-02-13 05:00:00 | Alkermes Targets Bipolar Disorder and Schizophrenia

2020-02-10 09:28:02 | Alkermes ALKS to Report Q4 Earnings: What's in Store?

2020-02-06 16:00:00 | Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2019 Financial Results

2020-02-06 12:30:05 | Alkermes ALKS to Report Q4 Results: Wall Street Expects Earnings Growth

2020-01-29 09:54:02 | Alkermes' ALKS NDA for ALKS 3831 Accepted by FDA for Review

2020-01-28 07:00:00 | Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder

2020-01-16 17:50:10 | Alkermes ALKS Stock Sinks As Market Gains: What You Should Know

2020-01-13 09:40:32 | Hedge Fund Favorites vs. Alkermes Plc ALKS In 2019

2020-01-13 05:11:12 | Does Alkermes plc NASDAQ:ALKS Have A High Beta?

2020-01-10 17:50:10 | Alkermes ALKS Gains As Market Dips: What You Should Know

2020-01-08 16:00:00 | Alkermes' Corporate Presentation to be Webcast at the 38th Annual J.P. Morgan Healthcare Conference

2020-01-06 11:40:04 | LGND vs. ALKS: Which Stock Is the Better Value Option?

2019-12-30 10:23:03 | Alnylam Stock Up More Than 61% YTD on Pipeline Progress

2019-12-30 09:44:02 | Flexion's FLXN Stock Up on FDA Approval for Zilretta sNDA

2019-12-26 07:22:12 | New Strong Buy Stocks for December 26th

2019-12-24 13:12:06 | Seattle Genetics Submits NDA to FDA for Tucatinib Combo

2019-12-20 17:50:10 | Alkermes ALKS Stock Sinks As Market Gains: What You Should Know